Fibrin clot properties and their modulation in thrombotic disorders

Summary

Accumulating evidence indicates that accelerated formation of fibrin clots composed of compact, highly-branched networks with thin fibres which are relatively resistant to plasmin-mediated lysis can be commonly observed in patients with venous or arterial thrombosis. This review discusses characteristics of fibrin clot structure and function in patients with various thromboembolic manifestations, in particular myocardial infarction, ischaemic stroke and venous thromboembolism, based on the publications till December 2013. Moreover, factors will be presented that in vivo unfavourably determine altered fibrin clot properties in thrombotic disorders and modalities that can improve clot phenotype.

Keywords

Fibrin clot - fibrinolysis - thrombosis

• References

• 1 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 03: 1894-1904.
• 2 Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 05 (Suppl. 01) 116-124.
• 3 Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011; 31: 494-499.
• 4 Weisel JW, Litvinov RI. Mechanisms of fibrin polymerisation and clinical implications. Blood 2013; 121: 1712-1719.
• 5 Hategan A, Gersh KC, Safer D. et al. Visualisation of the dynamics of fibrin clot growth 1 molecule at a time by total internal reflection fluorescence microscopy. Blood 2013; 121: 1455-1458.
• 6 Liu W, Jawerth LM, Sparks EA. et al. Fibrin fibres have extraordinary extensibility and elasticity. Science 2006; 313: 634.
• 7 Muszbek L, Bereczky Z, Bagoly Z. et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931-972.
• 8 Falvo MR, Gorkun OV, Lord ST. The molecular origins of the mechanical properties of fibrin. Biophys Chem 2010; 152: 15-20.
• 9 Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008; 06: 161-180.
• 10 Longstaff C, Thelwell C, Williams SC. et al. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117: 661-668.
• 11 Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Medicinal Chem 2008; 06: 161-180.
• 12 Carr ME. Fibrin formed in plasma is composed of fibres more massive than those formed from purified fibrinogen. Thromb Haemost 1988; 59: 535-539.
• 13 Carr Jr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995; 06: 567-573.
• 14 Undas A, Ariens RAS. Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
• 15 Cilia La Corte AL, Philippou H, Ariëns RA. Role of fibrin structure in thrombosis and vascular disease. Adv Protein Chem Struct Biol 2011; 83: 75-127.
• 16 Ariëns RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (Suppl. 01) 294-305.
• 17 Chernysh IN, Nagaswami C, Purohit PK. et al. Fibrin clots are equilibrium polymers that can be remodeled without proteolytic digestion. Sci Rep 2012; 02: 879.
• 18 Gersh KC, Edmondson KE, Weisel JW. Flow rate and fibrin fibre alignment. J Thromb Haemost 2010; 08: 2826-2828.
• 19 Campbell RA, Aleman M, Gray LD. et al. Flow profoundly influences fibrin network structure: implications for fibrin formation and clot stability in haemostasis. Thromb Haemost 2010; 104: 1281-1284.
• 20 Neeves KB, Illing DA, Diamond SL. Thrombin flux and wall shear rate regulate fibrin fibre deposition state during polymerisation under flow. Biophys J 2010; 98: 1344-1352.
• 21 Collet JP, Park D, Lesty C. et al. Influence of fibrin network conformation and fibrin fibre diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
• 22 Litvinov RI, Weisel JW. Shear strengthens fibrin: the knob-hole interactions display ‘catch-slip’ kinetics. J Thromb Haemost 2013; 11: 1933-1935.
• 23 Mazur P, Sobczyński R, Ząbczyk M. et al. Architecture of fibrin network inside thrombotic material obtained from the right atrium and pulmonary arteries: flow and location matter. J Thromb Thrombolysis 2013; 35: 127-129.
• 24 Marek G, Kablak-Ziembicka A, Stepien E. et al. Architecture of the thrombi removed from coronary artery bypass grafts in a patient with acute myocardial infarction. J Thromb Thrombolysis 2010; 30: 372-374.
• 25 Campbell RA, Overmyer KA, Bagnell R. et al. Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. Arterioscler Thromb Vasc Biol 2008; 28: 2247-2254.
• 26 Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation. Blood 2009; 114: 4886-4896.
• 27 Varin R, Mirshahi S, Mirshahi P. et al. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban. Thromb Res 2013; 131: e100-109.
• 28 Lipinski B, Pretorius E, Oberholzer HM, van der Spuy WJ. Interaction of fibrin with red blood cells: the role of iron. Ultrastruct Pathol 2012; 36: 79-84.
• 29 Wohner N, Sótonyi P, Machovich R. et al. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol 2011; 31: 2306-2313.
• 30 Longstaff C, Varjú I, Sótonyi P. et al. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem 2013; 288: 6946-6956.
• 31 Budaj M, Poljak Z, Ďuriš I. et al. Microparticles: a component of various diseases. Pol Arch Med Wewn 2012; 122 (Suppl. 01) 24-29.
• 32 Aleman MM, Gardiner C, Harrison P. et al. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 2011; 09: 2251-2261.
• 33 Undas A, Stepień E, Rudziński P. et al. Architecture of a pulmonary thrombus removed during embolectomy in a patient with acute pulmonary embolism. J Thorac Cardiovasc Surg 2010; 140: e40-41.
• 34 Lisman T, Leebeek FWG, Mosnier LO. et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
• 35 Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 15: 1102-1105.
• 36 Meltzer ME, Lisman T, de Groot PG. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
• 37 de Fouw NJ, van Tilburg NH, Haverkate F. et al. Activated protein C accelerates clot lysis by virtue of its anticoagulant activity. Blood Coagul Fibrinolysis 1993; 04: 201-210.
• 38 de Fouw NJ, de Jong YF, Haverkate F. et al. Activated protein C increases fibrin clot lysis by neutralisation of plasminogen activator inhibitor--no evidence for a cofactor role of protein S. Thromb Haemost 1988; 60: 328-333.
• 39 Gruber A, Mori E, del Zoppo GJ. et al. Alteration of fibrin network by activated protein C. Blood 1994; 83: 2541-2548.
• 40 Bajzar L, Nesheim M. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993; 268: 8608-8616.
• 41 Traby L, Kollars M, Eischer L. et al. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS One 2012; 07: e51447.
• 42 Meltzer ME, Lisman T, Doggen CJ. et al. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 05: e97.
• 43 Skov J, Sidelmann JJ, Bladbjerg EM. et al. Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke. Blood Coagul Fibrinolysis 2014; 25: 61-66.
• 44 Hoekstra J, Guimares AHC, Leebeek FW. et al. European Network for Vascular Disorders of the Liver (EN-Vie). Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood 2010; 115: 388-395.
• 45 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
• 46 Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost 2012; 107: 1180-1182.
• 47 Undas A, Cieśla-Dul M, Drąźkiewicz T. et al. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res 2012; 130: e184-187.
• 48 Undas A, Ciesla-Dul M, Drąźkiewicz T. et al. Prothrombotic plasma fibrin clot phenotype is predictive of recurrent venous thromboembolism following discontinuation of anticoagulant therapy. J Thromb Haemost. 2013 PA 1.14–4.
• 49 Krzek M, Ciesla-Dul M, Zabczyk M. et al. Fibrin clot properties in women heterozygous for factor V Leiden mutation: effects of oral contraceptives. Thromb Res 2012; 130: e216-221.
• 50 Celinska-Lowenhoff M, Iwaniec T, Alhenc-Gelas M. et al. Arterial and venous thrombosis and prothrombotic fibrin clot phenotype in a Polish family with type 1 antithrombin deficiency (antithrombin Krakow). Thromb Haemost 2011; 106: 379-381.
• 51 Meltzer ME, Hasstedt SJ, Vossen CY. et al. Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred. J Thromb Haemost 2011; 09: 1383-1390.
• 52 Celinska-Lowenhoff M, Padjas A, Iwaniec T. et al. Fibrin clot properties in patients with antiphospholipid syndrome. J Thromb Haemost. 2013 AS 08.3
• 53 Cellai AP, Lami D, Antonucci E. et al. Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity. J Thromb Thrombolysis. 2013 Epub ahead of print
• 54 Morris TA, Marsh JJ, Chiles PG. et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 2006; 173: 1270-1275.
• 55 Morris TA, Marsh JJ, Chiles PG. et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114: 1929-1936.
• 56 Marsh JJ, Chiles PG, Liang NC. et al. Chronic thromboembolic pulmonary hypertension-associated dysfibrinogenemias exhibit disorganized fibrin structure. Thromb Res 2013; 132: 729-734.
• 57 Silvain J, Collet JP, Nagaswami C. et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57: 1359-1367.
• 58 Undas A, Szuldrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551-558.
• 59 Undas A, Wiek I, Stepien E. et al. Hyperglycemia is associated with enhanced thrombin formation, platelet activation and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 2008; 31: 1590-1595.
• 60 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 61 Meltzer ME, Doggen CJ, de Groot PG. et al. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009; 145: 121-127.
• 62 Mills JD, Ariëns RA, Mansfield MW. et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
• 63 Leander K, Blombäck M, Wallén H. et al. Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction. Thromb Haemost 2012; 107: 1092-1099.
• 64 Undas A, Zalewski J, Krochin M. et al. Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol 2010; 30: 278-282.
• 65 Siegerink B, Meltzer ME, de Groot PG. et al. Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study. Br J Haematol 2012; 156: 252-258.
• 66 Sharma S, Farrington K, Kozarski R. et al. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J 2013; 34: 354-363.
• 67 Undas A, Kolarz M, Kopeć G. et al. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 2008; 23: 2010-2015.
• 68 Alzahrani SH, Hess K, Price JF. et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 2012; 97: E2282-2287.
• 69 Konieczyńska M, Fil K, Bazanek M. et al. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost 2014; 111: 685-693.
• 70 Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972-5979.
• 71 Martinez M, Weisel JW, Ischiropoulos H. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots. Free Radic Biol Med 2013; 65: 411-418.
• 72 Weigandt KM, White N, Chung D. et al. Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen. Biophys J 2012; 103: 2399-2407.
• 73 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-142.
• 74 Marder VJ, Chute DJ, Starkman S. et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischaemic stroke. Stroke 2006; 37: 2086-2093.
• 75 Liebeskind DS, Sanossian N, Yong WH. et al. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke 2011; 42: 1237-1243.
• 76 Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischaemic stroke: relation to neurological deficit. Thromb Res 2010; 125: 357-361.
• 77 Undas A, Podolec P, Zawilska K. et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischaemic stroke. Stroke 2009; 40: 1499-1501.
• 78 Rooth E, Wallen NH, Blombäck M. et al. Decreased fibrin clot network permeability and impaired fibrinolysis in the acute and convalescent phase of ischaemic stroke. Thromb Res 2011; 127: 51-56.
• 79 Ząbczyk M, Majewski J, Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Med Wewn 2011; 121: 400-407.
• 80 Yuki I, Kan I, Vinters HV. et al. The impact of thromboemboli histology on the performance of a mechanical thrombectomy device. AJNR Am J Neuroradiol 2012; 33: 643-648.
• 81 Karska-Basta I, Kubicka-Trząska A, Romanowska-Dixon B. et al. Altered fibrin clot properties in patients with retinal vein occlusion. J Thromb Haemost 2011; 09: 2513-2515.
• 82 Cellai AP, Lami D, Fedi S. et al. A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion. Atherosclerosis 2012; 224: 97-101.
• 83 Walus-Miarka M, Wolkow P, Cyganek K. et al. Altered fibrin-clot properties are associated with retinopathy in type 2 diabetes mellitus. Diabetes Metab 2012; 38: 462-465.
• 84 Ciurus T, Undas A, Lelonek M. Unexplained thrombosis of the aortic arch with distal embolisation in a patient with altered fibrin clot properties. Arch Med Sci 2012; 08: 733-735.
• 85 Undas A, Kaczmarek P, Sladek K. et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease: beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102: 1176-1182.
• 86 Kwaśny-Krochin B, Gluszko P, Undas A. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. Thromb Res 2010; 126: e11-e16.
• 87 Owczarek D, Cibor D, Sałapa K. et al. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism. Inflamm Bowel Dis 2013; 19: 2616-2624.
• 88 Salonen EM, Vartio T, Hedman K. Binding of fibronectin by the acute phase C-reactive protein. J Biol Chem 1984; 259: 1496-1501.
• 89 Okraska-Bylica A, Wilkosz T, Słowik L. et al. Altered fibrin clot properties in patients with premature peripheral artery disease. Pol Arch Med Wewn 2012; 122: 608-615.
• 90 Undas A, Plicner D, Stepien E. et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost 2007; 05: 1988-1990.
• 91 de Lange Z, Pieters M, Jerling JC. et al. Plasma clot lysis time and its association with cardiovascular risk factors in black Africans. PLoS One 2012; 07: e48881.
• 92 Jennewein C, Tran N, Paulus P. et al. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med 2011; 17: 568-573.
• 93 Ostrowski SR, Berg RM, Windeløv NA. et al. Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteers. PLoS One 2013; 08: e59368.
• 94 Scott DJ, Prasad P, Philippou H. et al. Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size. Arterioscler Thromb Vasc Biol 2011; 31: 3004-3010.
• 95 Natorska J, Marek G, Hlawaty M. et al. Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties. Thromb Haemost 2011; 105: 254-260.
• 96 Hooper JM, Stuijver DJ, Orme SM. et al. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. J Clin Endocrinol Metab 2012; 97: 1463-1473.
• 97 Undas A, Nowakowski T, Ciesla-Dul M. et al. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis 2011; 215: 481-486.
• 98 Ajjan RA, Standeven KF, Khanbhai M. et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009; 29: 712-717.
• 99 Svensson J, Bergman AC, Adamson U. et al. Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study. Biochem Biophys Res Commun 2012; 421: 335-342.
• 100 Undas A, Celinska-Lowenhoff M, Lowenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 04: 1029-1036.
• 101 Rajzer M, Wojciechowska W, Kawecka-Jaszcz K. et al. Fibrin clot properties in arterial hypertension and their modification by antihypertensive medication. Thromb Res 2012; 130: 99-103.
• 102 Undas A, Brozek J, Jankowski M. et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006; 26: 1397-1404.
• 103 Pieters M, Covic N, van der Westhuizen FH. et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost 2008; 99: 691-700.
• 104 Stępień E, Miszalski-Jamka T, Kapusta P. et al. Beneficial effect of cigarette smoking cessation on fibrin clot properties. J Thromb Thrombolysis 2011; 32: 177-182.
• 105 Gajos G, Zalewski J, Rostoff P. et al. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 2011; 31: 696-702.
• 106 Kleinegris MC, Ten Cate-Hoek AJ, Ten Cate H. Coagulation and the vessel wall in thrombosis and atherosclerosis. Pol Arch Med Wewn 2012; 122: 557-566.
• 107 Undas A. Atherosclerosis and venous thromboembolism - similarities. Kardiol Pol 2013; 71: 1115-1120.